The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Molecules versus cells for Hodgkin lymphoma management
Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MI, discusses the use of immunological molecules versus cellular therapy in the management of Hodgkin Lymphoma. A plethora of data is emerging that demonstrates the potential of numerous agents, including CAR T-cells, bispecific antibodies, and other immunologically active agents. Prof. Ansell comments that currently, one category has not shown to be superior than the other, with exciting data coming out to support the use of both. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
